CSIMarket
 
Atossa Therapeutics Inc   (ATOS)
Other Ticker:  
 
 
Price: $1.2900 $0.09 7.500%
Day's High: $1.295 Week Perf: 7.5 %
Day's Low: $ 1.15 30 Day Perf: 25.24 %
Volume (M): 1,202 52 Wk High: $ 1.39
Volume (M$): $ 1,551 52 Wk Avg: $0.85
Open: $1.17 52 Wk Low: $0.59



 Market Capitalization (Millions $) 162
 Shares Outstanding (Millions) 126
 Employees 9
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -30
 Cash Flow (TTM) (Millions $) -42
 Capital Exp. (TTM) (Millions $) 0

Atossa Therapeutics Inc
Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington that is primarily focused on developing innovative therapies that can prevent and treat breast cancer, as well as other medical conditions that are related to breast health. The companyes mission is to improve the lives of patients by creating new treatments that are safe, effective, and patient-friendly.

Atossa Therapeutics has a number of proprietary products and technologies that it is developing for breast cancer and other indications. One of the companyes flagship products is Endoxifen, which is a potent selective estrogen receptor modulator (SERM) that can be used to reduce the risk of developing breast cancer. Endoxifen has shown promising results in early-stage clinical trials, and the company is currently conducting more comprehensive clinical trials to evaluate its safety and efficacy.

In addition to Endoxifen, Atossa Therapeutics has also developed a range of other products that are designed to treat breast cancer and improve breast health. These products include:

- Topical Endoxifen: This is a topical form of Endoxifen that can be applied directly to the breast tissue. It is being developed for use in women who have been diagnosed with precancerous breast lesions or who are at high risk of developing breast cancer.
- Oral Endoxifen: This is an oral form of Endoxifen that can be taken by women who have been diagnosed with breast cancer or who are at high risk of developing the disease. It is currently in clinical trials to evaluate its safety and efficacy.
- Immunotherapies: Atossa Therapeutics is also developing a range of immunotherapies that can be used to treat breast cancer. These therapies are designed to stimulate the bodyes immune system to target and eliminate cancer cells.
- Breast Health Products: The company has also developed a range of products that are designed to improve breast health and reduce the risk of breast cancer. These products include a breast pump and a diagnostic device that can be used to detect breast cancer at an early stage.

Overall, Atossa Therapeutics is a leader in the development of innovative therapies for breast cancer and other breast health-related conditions. The companyes proprietary products and technologies show great promise in the fight against breast cancer, and its ongoing clinical trials are expected to provide important insights into the safety and efficacy of these products.


   Company Address: 107 Spring Street Seattle 98104 WA
   Company Phone Number: 588-0256   Stock Exchange / Ticker: NASDAQ ATOS
   ATOS is expected to report next financial results on March 21, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Management Announcement

Atossa Therapeutics Achieves Compliance with Nasdaq Minimum Bid Price Requirement

Published Mon, Mar 18 2024 12:30 PM UTC

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company, announced on March 18, 2024, that it has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). This comes after receiving written notice on March...

Clinical Study

Atossa Therapeutics Presents Promising Phase 2 EVANGELINE Trial Data at AACR Annual Meeting

Published Wed, Mar 6 2024 1:30 PM UTC

Data from Atossa's Phase 2 EVANGELINE Clinical Trial to be Presented at AACR Annual MeetingAtossa Therapeutics, Inc. is set to present data from the 40mg pharmacokinetic (PK) run-in cohort of its Phase 2 EVANGELINE study at the upcoming American Association for Cancer Research (AACR) Annual Meeting. The event will take place from April 5-10, 2024, in San Diego, California. T...

Clinical Study

Atossa Therapeutics Initiates Innovative Study to Evaluate Non-Surgical Treatment Option for Breast Cancer Patients with DCIS.

Published Thu, Feb 22 2024 1:30 PM UTC

Atossa Therapeutics, a leading clinical stage biopharmaceutical company focused on addressing unmet needs in oncology, recently announced a significant development in the ongoing RECAST DCIS study. The company disclosed that the first patient has been administered Atossa's proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, as part of the study. This gro...

Clinical Study

Atossa Therapeutics Advances Towards Personalized Therapies for Breast Cancer with Completion of (Z)-Endoxifen Enrollment in I-SPY 2 Clinical Trial

Published Wed, Feb 7 2024 1:30 PM UTC

Atossa Therapeutics Successfully Completes Enrollment for (Z)-Endoxifen Arm in Phase 2 I-SPY 2 Clinical Trial for Breast Cancer TreatmentSeattle-based biopharmaceutical company, Atossa Therapeutics, has accomplished a significant milestone by announcing the full enrollment of the (Z)-endoxifen arm in its ongoing Phase 2 I-SPY 2 clinical trial. This trial focuses on evaluatin...

Management Announcement

Atossa Therapeutics Takes Strides in Transforming Breast Cancer Treatment Landscape

Published Tue, Jan 9 2024 1:30 PM UTC


In our rapidly advancing world of medical research and development, cancer remains one of the most formidable challenges, particularly breast cancer, which continues to affect millions of women worldwide. However, in an era of groundbreaking advancements, pharmaceutical company Atossa Therapeutics, Inc. (Nasdaq: ATOS) is taking great strides in pioneering innovative med...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com